JP2021508255A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021508255A5 JP2021508255A5 JP2020554353A JP2020554353A JP2021508255A5 JP 2021508255 A5 JP2021508255 A5 JP 2021508255A5 JP 2020554353 A JP2020554353 A JP 2020554353A JP 2020554353 A JP2020554353 A JP 2020554353A JP 2021508255 A5 JP2021508255 A5 JP 2021508255A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- antibody
- cancer
- fold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229960005386 ipilimumab Drugs 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000005975 antitumor immune response Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229960000106 biosimilars Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- -1 coatings Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022093122A JP7464300B2 (ja) | 2017-12-20 | 2022-06-08 | Ｃｔｌａ－４に結合する抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607917P | 2017-12-20 | 2017-12-20 | |
| US62/607,917 | 2017-12-20 | ||
| PCT/CN2018/122190 WO2019120232A1 (en) | 2017-12-20 | 2018-12-19 | Antibodies binding ctla-4 and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022093122A Division JP7464300B2 (ja) | 2017-12-20 | 2022-06-08 | Ｃｔｌａ－４に結合する抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021508255A JP2021508255A (ja) | 2021-03-04 |
| JP2021508255A5 true JP2021508255A5 (enExample) | 2021-08-05 |
| JP7087107B2 JP7087107B2 (ja) | 2022-06-20 |
Family
ID=66994401
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554353A Active JP7087107B2 (ja) | 2017-12-20 | 2018-12-19 | Ｃｔｌａ－４に結合する抗体およびその使用 |
| JP2022093122A Active JP7464300B2 (ja) | 2017-12-20 | 2022-06-08 | Ｃｔｌａ－４に結合する抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022093122A Active JP7464300B2 (ja) | 2017-12-20 | 2022-06-08 | Ｃｔｌａ－４に結合する抗体およびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11098122B2 (enExample) |
| EP (2) | EP4295915A3 (enExample) |
| JP (2) | JP7087107B2 (enExample) |
| KR (1) | KR102476887B1 (enExample) |
| CN (2) | CN111655728B (enExample) |
| AU (1) | AU2018391831B2 (enExample) |
| BR (1) | BR112020012364A2 (enExample) |
| CA (1) | CA3085861C (enExample) |
| DK (1) | DK3710484T5 (enExample) |
| ES (1) | ES2965187T3 (enExample) |
| FI (1) | FI3710484T3 (enExample) |
| IL (1) | IL275391B2 (enExample) |
| MX (1) | MX2020006585A (enExample) |
| PH (1) | PH12020550933A1 (enExample) |
| PL (1) | PL3710484T3 (enExample) |
| RU (1) | RU2756100C1 (enExample) |
| SG (1) | SG11202005692WA (enExample) |
| WO (1) | WO2019120232A1 (enExample) |
| ZA (1) | ZA202003641B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3710484T5 (da) * | 2017-12-20 | 2024-08-26 | Harbour Biomed Shanghai Co Ltd | Ctla-4-bindende antistoffer og anvendelser deraf |
| EP3898677A1 (en) | 2018-12-21 | 2021-10-27 | OSE Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| EP4041767A1 (en) * | 2019-09-26 | 2022-08-17 | StCube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| CN112569183B (zh) * | 2020-12-11 | 2022-12-09 | 上海赛金生物医药有限公司 | 一种抗ctla-4抗体及融合蛋白的制剂 |
| WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| CA3213917A1 (en) | 2021-04-09 | 2022-10-13 | Nicolas Poirier | New scaffold for bifunctional molecules with improved properties |
| US20240270847A1 (en) * | 2021-04-21 | 2024-08-15 | Harbour Biomed (Shanghai) Co., Ltd. | Antibody binding ctla-4 and use thereof |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| JP2025525886A (ja) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| WO2024049203A1 (ko) * | 2022-09-02 | 2024-03-07 | 주식회사 시클리드 | 항 ctla-4 모노클로날 항체 및 이의 용도 |
| EP4687990A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK368882A (da) | 1981-08-25 | 1983-02-26 | Alan John Kingsman | Expessions vektorer |
| US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| US4977092A (en) | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4661454A (en) | 1983-02-28 | 1987-04-28 | Collaborative Research, Inc. | GAL1 yeast promoter linked to non galactokinase gene |
| US5139936A (en) | 1983-02-28 | 1992-08-18 | Collaborative Research, Inc. | Use of the GAL1 yeast promoter |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| ATE54167T1 (de) | 1984-12-06 | 1990-07-15 | Fina Research | Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden. |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5063154A (en) | 1987-06-24 | 1991-11-05 | Whitehead Institute For Biomedical Research | Pheromone - inducible yeast promoter |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5298418A (en) | 1991-09-16 | 1994-03-29 | Boyce Thompson Institute For Plant Research, Inc. | Cell line isolated from larval midgut tissue of Trichoplusia ni |
| AU5103293A (en) | 1992-09-14 | 1994-04-12 | Oklahoma State University | Immortalized cells and uses therefor |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US5955349A (en) | 1996-08-26 | 1999-09-21 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
| US5716808A (en) | 1995-11-09 | 1998-02-10 | Zymogenetics, Inc. | Genetic engineering of pichia methanolica |
| US5854039A (en) | 1996-07-17 | 1998-12-29 | Zymogenetics, Inc. | Transformation of pichia methanolica |
| US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| DK2112166T3 (en) * | 1998-12-23 | 2019-02-04 | Pfizer | Human monoclonal antibodies to CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| EP1261376A1 (en) * | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| CA2658221C (en) * | 2001-04-27 | 2012-11-27 | Kyowa Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| CA2560919A1 (en) * | 2004-03-26 | 2005-10-06 | Pfizer Products Inc. | Uses of anti-ctla-4 antibodies |
| EP4353819A3 (en) | 2004-07-22 | 2024-07-17 | Erasmus University Medical Center Rotterdam | Binding molecules |
| US20060240006A1 (en) | 2005-04-20 | 2006-10-26 | Chishih Chu | Novel antibody structures derived from human germline sequences |
| CL2007003291A1 (es) * | 2006-11-15 | 2008-07-04 | Medarex Inc | Anticuerpo monoclonal humano aislado que enlaza la proteina btla o fragmentos del mismo; acido nucleico que lo codifica; metodo de produccion; composicion e inmunoconjugado que los comprende; y metodo para inhibir el crecimiento de celulas de tumor e |
| GB0903325D0 (en) * | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| GB0905023D0 (en) * | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| KR101535341B1 (ko) * | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| CN104292334B (zh) * | 2014-04-25 | 2018-11-27 | 河南省健康伟业生物医药研究股份有限公司 | 一种全人源抗ctla-4单克隆抗体、制备方法及应用 |
| CA2976446A1 (en) * | 2015-02-13 | 2016-08-18 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind ctla4 |
| CN106188297B (zh) | 2015-07-20 | 2019-09-27 | 广西医科大学 | 抗CTLA-4的纳米抗体Nb91及其制备方法与应用 |
| CN106046165B (zh) | 2015-07-20 | 2019-05-21 | 广西医科大学 | 抗CTLA-4的纳米抗体Nb30及其制备方法与应用 |
| CN106046164B (zh) | 2015-07-20 | 2019-10-25 | 广西医科大学 | 抗CTLA-4的纳米抗体Nb36及其制备方法与应用 |
| CN106220732B (zh) * | 2015-07-20 | 2019-05-21 | 广西医科大学 | 抗CTLA-4的纳米抗体Nb16及其制备方法与应用 |
| CN107400166A (zh) * | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
| DK3710484T5 (da) * | 2017-12-20 | 2024-08-26 | Harbour Biomed Shanghai Co Ltd | Ctla-4-bindende antistoffer og anvendelser deraf |
-
2018
- 2018-12-19 DK DK18892518.4T patent/DK3710484T5/da active
- 2018-12-19 US US16/224,825 patent/US11098122B2/en active Active
- 2018-12-19 RU RU2020123859A patent/RU2756100C1/ru active
- 2018-12-19 BR BR112020012364-1A patent/BR112020012364A2/pt unknown
- 2018-12-19 JP JP2020554353A patent/JP7087107B2/ja active Active
- 2018-12-19 IL IL275391A patent/IL275391B2/en unknown
- 2018-12-19 CA CA3085861A patent/CA3085861C/en active Active
- 2018-12-19 SG SG11202005692WA patent/SG11202005692WA/en unknown
- 2018-12-19 PL PL18892518.4T patent/PL3710484T3/pl unknown
- 2018-12-19 MX MX2020006585A patent/MX2020006585A/es unknown
- 2018-12-19 ES ES18892518T patent/ES2965187T3/es active Active
- 2018-12-19 EP EP23205205.0A patent/EP4295915A3/en active Pending
- 2018-12-19 AU AU2018391831A patent/AU2018391831B2/en active Active
- 2018-12-19 CN CN201880083036.7A patent/CN111655728B/zh active Active
- 2018-12-19 KR KR1020207020932A patent/KR102476887B1/ko active Active
- 2018-12-19 FI FIEP18892518.4T patent/FI3710484T3/fi active
- 2018-12-19 EP EP18892518.4A patent/EP3710484B1/en active Active
- 2018-12-19 WO PCT/CN2018/122190 patent/WO2019120232A1/en not_active Ceased
- 2018-12-19 CN CN202210126917.0A patent/CN114409786B/zh active Active
-
2020
- 2020-06-17 ZA ZA2020/03641A patent/ZA202003641B/en unknown
- 2020-06-18 PH PH12020550933A patent/PH12020550933A1/en unknown
-
2021
- 2021-07-14 US US17/375,940 patent/US12240905B2/en active Active
-
2022
- 2022-06-08 JP JP2022093122A patent/JP7464300B2/ja active Active